- 1
- 2
- 3
- 4
Takeda’s Mission To Improve Communication With Patients, Sites, And CROs
- 1
- 2
- 3
- 4
Diversity & Inclusion Through The Eyes Of Two Female Pharma Executives
- 1
- 2
- 3
- 4
A New Model For A New Era Of Psychedelic Therapy
ALSO IN THIS MONTH'S ISSUE
-
![CtW - CinCor_450x300]( "Companies To Watch: CinCor Pharma")
Companies To Watch: CinCor PharmaCinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.
-
![China’s biopharma industry_450x300]( "What Does The Future Hold For China’s Biopharma Industry?")
What Does The Future Hold For China’s Biopharma Industry?Chinese biopharma stock prices have been on a roller coaster ride, with some composites reaching historical highs in June 2021 but heading south ever since. In this article, we deep dive into what enabled this sudden rise and examine whether the future of China’s biopharma industry looks as bleak as the stock market suggests.
-
![CoCrystal Pharma_450x300]( "CoCrystal’s Co-CEOs")
CoCrystal’s Co-CEOsMost biopharma industry observers would agree the leadership of a company by two co-equal CEOs is a rare thing. But when it does happen, the unusual arrangement offers useful insights.
-
![Diagnostics in Neurology and Alzheimers_450x300]( "3 Approaches For Developing Better Drugs To Treat Brain Disorders")
3 Approaches For Developing Better Drugs To Treat Brain DisordersThree organizations pursuing three different strategies for new drug development have one thing in common: optimism about the future of treatments for intractable brain disorders.
BEYOND THE PRINTED PAGE
-
MAPS: Walking The Talk On Intellectual Property?4/29/2022
Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it against competitors?
-
Where Patients Meet Policy: The EveryLife Foundation For Rare Diseases4/1/2022
The year before he founded Ultragenyx, Emil Kakkis created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization focused on the “equitable development of and access to lifesaving diagnoses, treatments, and cures.” We caught up with Annie Kennedy, chief of policy and advocacy at the EveryLife Foundation, to learn more about the issues and policies the foundation is prioritizing this year.
-
Ever Learn A Lesson The Hard Way?1/24/2022
Bernard Coulie, M.D., Ph.D., president and CEO of Pliant Therapeutics, a company developing treatments for fibrotic diseases, shares a lesson learned the hard way involving an exit from a previous startup.
WEB-EXCLUSIVE EDITORIAL
NEWSLETTER ARCHIVE
- 06.27.22 -- Why Karen Correa Built Takeda's Study Optimization Team
- 06.27.22 -- Micronization Technology: HPAPI Drug Product Development And Manufacturing
- 06.24.22 -- Rare Disease Product Launch Success
- 06.23.22 -- Scale Up Cell Therapy Production At The Pace Of Your Business
- 06.23.22 -- Smarter Solutions For Your Cell Line Development
JUNE 2022 DIGITAL EDITION
LIFE SCIENCE LEADER CONTENT COLLECTIONS
2022 CMO & CRO AWARDS EDITION
ASK THE BOARD
- What Key Elements Should A Company Consider When Setting Up An Expanded-Access Program For An Experimental Drug Candidate?
- What Kinds Of Resources And Assistance Can State-Level Industry Trade Associations Offer Start-Up And Early-Stage Biopharmaceutical Companies?
- What Should Biopharma Companies With Drugs Moving Into Phase 3 Clinical Trials Prioritize With Respect To Supporting Payer Access In The U.S.?